<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103466</url>
  </required_header>
  <id_info>
    <org_study_id>CP204OC</org_study_id>
    <nct_id>NCT01103466</nct_id>
  </id_info>
  <brief_title>Investigation of the Performance of Ostomy Base Plate</brief_title>
  <official_title>A Randomised Controlled Cross-over Study Investigating the Performance and Safety of the Ostomy Base Plate SSH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of Atlas (new base plate) on the
      degree of leakage under the base plate compared to SenSura and Conform 2. Our hypothesis is
      that Atlas will do better than the two comparator products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peristomal skin problems are reported to have a negative impact on the quality of life of
      people with a stoma and cause one third of all visits to a stoma care nurse. Stoma effluent
      in contact with the peristomal skin (leakage) appears to predispose patients to peristomal
      skin problems. To protect the skin against effluent, the appliance used for collection of
      stoma effluent should completely cover the peristomal skin close to the stoma. Coloplast has
      developed a new base plate (SSH) to improve security and increase comfort by minimizing
      leakage (seeping under the base plate) risk and thereby also the leakage related peristomal
      skin problems.

      The purpose with this clinical study is to evaluate the effect of the new base plate on the
      degree of leakage under the base plate compared to two existing base plates on the market.

      The study is a randomised controlled cross-over intervention study, where all study
      participants will test all three test products (SSH, Conform 2 and Sensura). Each test period
      will last 14 days. If 4 changes of base plates is not obtained during the 14 days, the test
      period will be prolonged until 4 base plate changes is obtained. However, the max test period
      of one type of product is 21 days. The participants will visit the study investigator at
      study start and at every shift to a new type of test product. At these visits they will
      answer questions about the tested product, have a peristomal skin examination and be
      instructed in how to use the next test products for the next treatment period. Evaluation of
      leakage and handling will occur via questionnaires the participants take home.

      80 healthy participants with an ileostomy will be included in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leakage Under the Base Plate</measure>
    <time_frame>At every change of base plate</time_frame>
    <description>Area of leakage under the base plate is recorded on a circular scale going from 0 fields to 24 fields where 0 is &quot;no leakage&quot; and 24 is &quot;complete leakage&quot; under the base plate.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <arm_group>
    <arm_group_label>New ostomy appliance (Atlas)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SenSura</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available ostomy appliance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conform 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available ostomy appliance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atlas</intervention_name>
    <description>Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.</description>
    <arm_group_label>New ostomy appliance (Atlas)</arm_group_label>
    <other_name>ostomy appliance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SenSura</intervention_name>
    <description>SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.</description>
    <arm_group_label>SenSura</arm_group_label>
    <other_name>ostomy appliance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conform 2</intervention_name>
    <description>Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.</description>
    <arm_group_label>Conform 2</arm_group_label>
    <other_name>Ostomy appliance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have given written Informed Consent

          2. Are at least 18 years old

          3. Had their ileostomy for minimum 3 months with a size between 20-40 mm

          4. Have mental capacity to understand study guidelines and questionnaires

          5. Are capable to changing base plate and pouches without help. The help of a caregiver
             is accepted.

          6. Experience leakage under the base plate at least one a week

          7. Are currently using a flat 2-piece base plate with mechanical coupling

          8. Have been evaluated by investigator (i.e. a health care professional) to have a stoma
             and peristomal skin condition that is acceptable for entering the study

        Exclusion Criteria:

          1. Pregnant or breast-feeding

          2. Currently suffering from peristomal skin problems where the skin is damaged or
             bleeding (red and broken / broken and bleeding) as clinically evaluated by the
             investigator.

          3. Currently receiving or have within the past 2 months received radio- and/or
             chemotherapy

          4. Currently using steroid product on peristomal skin (injections and oral treatment are
             accepted)

          5. Currently using a convex system

          6. Participating in other clinical studies or have previously participated in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lis H Poulsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <results_first_submitted>January 9, 2012</results_first_submitted>
  <results_first_submitted_qc>February 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ileostomy base plate</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a user database in Denmark.</recruitment_details>
      <pre_assignment_details>41 subjects were enrolled, however 6 subjects did not comply with the inclusion and exclusion criteria. Four of these were terminated before testing any products. Whereas two subjects were included in the safety population as the inclusion criteria violation was first discovered after they tested a product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atlas</title>
          <description>New base plate
All subjects tested this test product in one period during the study.
No parcipitants recieved the same study intervention more than once</description>
        </group>
        <group group_id="P2">
          <title>SenSura</title>
          <description>Commercially available base plate
All subjects tested this test product in one period during the study.
No parcipitants recieved the same study intervention more than once</description>
        </group>
        <group group_id="P3">
          <title>Conform2</title>
          <description>Commercially available base plate
All subjects tested this test product in one period during the study.
No parcipitants recieved the same study intervention more than once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period (14 +/- 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Period (14 +/- 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Period (14 +/- 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not satisfied with product</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 subjects were excluded from the ITT and PP population, and therefore not included in the baseline measurements</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Parcipitants</title>
          <description>All parcipitants recieved all three intervention and they are therefore combined into one group.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leakage Under the Base Plate</title>
        <description>Area of leakage under the base plate is recorded on a circular scale going from 0 fields to 24 fields where 0 is &quot;no leakage&quot; and 24 is &quot;complete leakage&quot; under the base plate.</description>
        <time_frame>At every change of base plate</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Atlas</title>
            <description>new base plate</description>
          </group>
          <group group_id="O2">
            <title>SenSura</title>
            <description>base plate</description>
          </group>
          <group group_id="O3">
            <title>Conform2</title>
            <description>base plate</description>
          </group>
        </group_list>
        <measure>
          <title>Leakage Under the Base Plate</title>
          <description>Area of leakage under the base plate is recorded on a circular scale going from 0 fields to 24 fields where 0 is &quot;no leakage&quot; and 24 is &quot;complete leakage&quot; under the base plate.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="5.0"/>
                    <measurement group_id="O2" value="5.5" spread="4.8"/>
                    <measurement group_id="O3" value="8.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from inclusion to the end of the three test periods (~43 days).</time_frame>
      <desc>The safety population contained 37 subjects, whereof two subjects were excluded from the ITT population due to inclusion criteria violation and did not try any test products.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atlas</title>
          <description>new base plate</description>
        </group>
        <group group_id="E2">
          <title>SenSura</title>
          <description>base plate</description>
        </group>
        <group group_id="E3">
          <title>Conform2</title>
          <description>base plate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>faeces leakage under base plate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lis Hentze Poulsen</name_or_title>
      <organization>Coloplast A/S</organization>
      <phone>4549111111</phone>
      <email>dklhp@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

